tolremo

THERAtRAME

The company develops small molecule inhibitors targeting tRNA epitranscriptomics to treat resistant and immune-refractory cancers for patients with limited therapeutic options.

KyDo Therapeutics

This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.

Fore Bio

This biotechnology company develops precision oncology therapies and small-molecule inhibitors for patients with unaddressed tumour mutations and hard-to-treat cancers.

KyDo

This biotechnology company develops small molecule inhibitors for the treatment of cancer variants in oncology patients.

Flindr Therapeutics

This company develops small molecule inhibitors for the precision treatment of cancer patients with specific tumor and host factors.

Alterome Therapeutics

This company develops small-molecule targeted therapies for cancer patients by using computational chemistry to address specific genetic mutations.

CasInvent Pharma

This company develops small molecule inhibitors targeting casein kinase 1 enzymes to treat patients with treatment-resistant cancers such as acute myeloid leukaemia and melanoma.

Flindr

The company develops small molecule inhibitors for precision oncology treatments to improve outcomes for cancer patients.